O’Melveny & Myers LLP represented Nektar Therapeutics (Nektar) in its underwritten public offering of 19 million shares of its common stock, raising approximately US$220.4 million.  The public offering closed on January 24, 2011.

 

Additionally, Nektar has granted the underwriter an option, exercisable for 30 days after January 19, 2011, to purchase up to 2.85 million additional shares of common stock to cover overallotments, if any.

 

The O’Melveny Silicon Valley team was led by partner Sam Zucker and counsel Jennifer DePalma.